Servier key figures
key figures
We help to drive therapeutic progress
As a global pharmaceutical Group, we help to drive therapeutic progress by investing over 20% of revenue from brand-name medicines in R&D each year.
About Servier
35th
largest pharmaceutical group worldwide
2nd
largest French pharmaceutical group
20%
Over 20% of revenue from brand-name medicines invested in R&D each year
70
Over 70 scientific partnerships and collaborations in 2022/2023
21,900
employees
96.5%
of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France
12
international patient organizations collaborated with Servier in 2023
Driving scientific and medical progress
4
therapeutic areas: oncology, cardiometabolism & veinous diseases, neuroscience and immuno-inflammation
35
projects in clinical development (including 12 new molecular entities) and 26 research projects (November 2024)
5th
leading pharmaceutical group in cardiology worldwide
1st
leading pharmaceutical group in hypertension worldwide
Global presence
150
Over 150 countries where the Group’s medicines are distributed
14
production sites
4
research centers
3
hubs (North and South America, Europe, Asia-Pacific) with 15 International Centers for Therapeutic Research
Social responsibility
-42%
target of reduction in our greenhouse gas emissions on scopes 1&2 in 2030 compared to 2021-2022 3
48%
of the Group’s managers are women as of 2022-2023
4.33/5
overall engagement score achieved by the Servier Group2
Financial performance
€5.3
billion in revenue in 2022-2023
(including €4 billion for brand-name medicines and €1.3 billion for generic activities)
€ 1
billion in EBITDA in 2022-2023 or 19.1% of Group revenue
[1] IQVIA, Analytics Link / World 75 countries – MAT Q1-2024
[2] Source: annual engagement survey conducted with the Gallup Institute – 2024 Group results
[3] Scope 1 emissions represent emissions directly linked to Group operations. Scope 2 emissions are linked to the purchase of electricity and energy for heating or cooling